Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02705339 | Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | May 17, 2016 | clinicaltrials |
| NCT02651506 | Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules | withdrawn | Phase 2 | 0 | St. Joseph's Healthcare HamiltonOTHER | 0 | May 12, 2016 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00768131 | A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01184287 | A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Tamir Biotechnology, Inc.INDUSTRY | 1 | Sep 2, 2015 | clinicaltrials |
| NCT01928160 | Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Jul 13, 2015 | clinicaltrials |
| NCT00697060 | A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | AmpliMed CorporationINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00903942 | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | University of RochesterOTHER | 1 | Apr 27, 2015 | clinicaltrials |
| NCT01048983 | Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 5, 2015 | clinicaltrials |
| NCT02297425 | A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Jan 12, 2015 | clinicaltrials |
| NCT01336543 | Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Syed JafriOTHER | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01913067 | Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC(CRANIAL) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Jul 24, 2014 | clinicaltrials |
| NCT00112060 | A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 1 / Phase 2 | 0 | Spectrum Pharmaceuticals, IncINDUSTRY | 2 | Mar 31, 2014 | clinicaltrials |
| NCT01256203 | Efficacy and Safety of a Sunscreen Against Porfimer Sodium-induced Phototoxicity to Visible Light | withdrawn | Phase 2 | 0 | Pinnacle Biologics Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT00256841 | Hypo-Hyperfractionated Chest Radiation for Non Small Cell Lung Cancer With Taxotere/Xeloda Combination Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | Clinical Oncology Research AssociatesOTHER | 1 | Jan 29, 2014 | clinicaltrials |
| NCT01533727 | CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2013 | clinicaltrials |
| NCT01504542 | Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Heat BiologicsINDUSTRY | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01674738 | TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV(SELECT-A) | withdrawn | Phase 2 | 0 | Aktion Bronchialkarzinom e.V.OTHER | 0 | Oct 11, 2013 | clinicaltrials |
| NCT01728181 | A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation | withdrawn | Phase 1 / Phase 2 | 0 | University of UtahOTHER | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00268255 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 16, 2013 | clinicaltrials |
| NCT00386555 | A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel. | withdrawn | Phase 2 | 0 | Arog Pharmaceuticals, Inc.INDUSTRY | 0 | Aug 9, 2012 | clinicaltrials |
| NCT00048087 | Iressa/Docetaxel in Non-Small-Cell Lung Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2012 | clinicaltrials |
| NCT01449357 | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors | withdrawn | Phase 2 | 0 | GenmabINDUSTRY | 0 | Oct 10, 2011 | clinicaltrials |
Data updated 22 days agoSource updated May 17, 2016source: clinicaltrials